At time of treatment with chemotherapy for advanced urothelial carcinoma, stratifying patients as non-elevated CRP (57.5% of patients), elevated to normalized CRP (30% of patients), and non-normalized CRP (12.5% of patients) groups held significant prognostic value (21). Here, CRP is linked to urothelial carcinoma.